Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.
Wang ZG, Williams LJ, Zhang XF, Zatorski A, Kudryashov V, Ragupathi G, Spassova M, Bornmann W, Slovin SF, Scher HI, Livingston PO, Lloyd KO, Danishefsky SJ. Wang ZG, et al. Among authors: livingston po. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2719-24. doi: 10.1073/pnas.97.6.2719. Proc Natl Acad Sci U S A. 2000. PMID: 10716997 Free PMC article.
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI. Slovin SF, et al. Cancer Immunol Immunother. 2005 Jul;54(7):694-702. doi: 10.1007/s00262-004-0598-5. Epub 2005 Feb 22. Cancer Immunol Immunother. 2005. PMID: 15726361 Free PMC article. Clinical Trial.
A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.
Slovin SF, Ragupathi G, Fernandez C, Jefferson MP, Diani M, Wilton AS, Powell S, Spassova M, Reis C, Clausen H, Danishefsky S, Livingston P, Scher HI. Slovin SF, et al. Vaccine. 2005 May 2;23(24):3114-22. doi: 10.1016/j.vaccine.2005.01.072. Vaccine. 2005. PMID: 15837210
On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.
Ragupathi G, Coltart DM, Williams LJ, Koide F, Kagan E, Allen J, Harris C, Glunz PW, Livingston PO, Danishefsky SJ. Ragupathi G, et al. Among authors: livingston po. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13699-704. doi: 10.1073/pnas.202427599. Epub 2002 Oct 1. Proc Natl Acad Sci U S A. 2002. PMID: 12359877 Free PMC article.
A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
Ragupathi G, Koide F, Sathyan N, Kagan E, Spassova M, Bornmann W, Gregor P, Reis CA, Clausen H, Danishefsky SJ, Livingston PO. Ragupathi G, et al. Among authors: livingston po. Cancer Immunol Immunother. 2003 Oct;52(10):608-16. doi: 10.1007/s00262-003-0399-2. Epub 2003 Jun 17. Cancer Immunol Immunother. 2003. PMID: 12811527 Free PMC article.
153 results